Evidence map›Paper›PMID 38488491›Full record

Trial reportThe Journal of clinical endocrinology and metabolism2024

Effects of Supplemental Vitamin D3, Omega-3 Fatty Acids on Physical Performance Measures in the VITamin D and OmegA-3 TriaL.

Sharon H Chou, Nancy R Cook, Gregory Kotler, Eunjung Kim, Trisha Copeland, I Min Lee, Peggy M Cawthon, Julie E Buring, JoAnn E Manson, Meryl S LeBoff

Open access · greenAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The Journal of clinical endocrinology and metabolism, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
3.6field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 11 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Observational
  4. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Sharon H ChouDivision of Endocrinology, Diabetes and Hypertension, Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA.ORCID 0000-0003-2582-050X
Nancy R CookDepartment of Medicine, Harvard Medical School, Boston, MA 02115, USA.
Gregory KotlerDivision of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02215, USA.
Eunjung KimDivision of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02215, USA.
Trisha CopelandDivision of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02215, USA.
I Min LeeDepartment of Medicine, Harvard Medical School, Boston, MA 02115, USA.
Peggy M CawthonDepartment of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA 94158, USA.
Julie E BuringDepartment of Medicine, Harvard Medical School, Boston, MA 02115, USA.
JoAnn E MansonDepartment of Medicine, Harvard Medical School, Boston, MA 02115, USA.
Meryl S LeBoffDivision of Endocrinology, Diabetes and Hypertension, Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA.ORCID 0000-0001-5797-4947
Brigham and Women's Hospital · USUniversity of California, San Francisco · US

Funding

Harvard Clinical and Translational Science CenterUL1TR001102 · NCATS · HARVARD MEDICAL SCHOOL · PI NADLER, LEE MARSHALL · 2013 to 2017
$106.2M
HARVARD CLINICAL AND TRANSLATIONAL SCIENCE CENTER (UL1)UL1RR025758 · NCRR · HARVARD MEDICAL SCHOOL · PI NADLER, LEE MARSHALL · 2008 to 2011
$91.4M
Harvard Clinical and Translational Science Center (UL1)UL1TR000170 · NCATS · HARVARD MEDICAL SCHOOL · PI NADLER, LEE MARSHALL · 2012 to 2013
$31.4M
VITamin D and omegA-3 triaL (VITAL)U01CA138962 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI BURING, JULIE E., MANSON, JOANN ELISABETH · 2009 to 2014
$23.6M
The VITamin D and OmegA-3 TriaL (VITAL)R01CA138962 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI BURING, JULIE E., MANSON, JOANN ELISABETH · 2015 to 2019
$20.9M
Skeletal Biology and Biomechanics (SBB) CoreP30AR075055 · NIAMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Wenhan Chang · 2019 to 2026
$7.1M
The VITamin D and OmegA-3 TriaL (VITAL): Post-Intervention Follow-UpR01AT011729 · NCCIH · BRIGHAM AND WOMEN'S HOSPITAL · PI Jun Li, JoAnn Elisabeth Manson · 2021 to 2026
$5.2M
VITamin D and OmegA-3 TriaL (VITAL): Interrelationship of Vitamin D and Vitamin K on BoneR01AR059775 · NIAMS · BRIGHAM AND WOMEN'S HOSPITAL · PI LEBOFF, MERYL SUSAN · 2012 to 2022
$3.9M
VITamin D OmegA-3 TriaL (VITAL): Fractures, Vitamin D and Genetic MarkersR01AR070854 · NIAMS · BRIGHAM AND WOMEN'S HOSPITAL · PI LEBOFF, MERYL SUSAN · 2018 to 2022
$2.8M
Vitamin D and Omega-3 Fatty Acids(VITAL Trial): Effects on FracturesR01AR060574 · NIAMS · BRIGHAM AND WOMEN'S HOSPITAL · PI LEBOFF, MERYL SUSAN · 2010 to 2013
$779k
Harvard Clinical and Translational Science CenterNational Center for Advancing Translational ScienceNational Institute of Arthritis Musculoskeletal and Skin DiseasesNCATS NIH HHS UL1 TR000170NCATS NIH HHS UL1 TR001102NCCIH NIH HHS 1 UL1 RR025758NCCIH NIH HHS R01 AT011729NCI NIH HHS R01 CA138962NCI NIH HHS U01 CA138962NCRR NIH HHS 1UL1TR001102NCRR NIH HHS UL1 RR025758NHLBI NIH HHSNIAMS NIH HHS P30 AR075055NIAMS NIH HHS R01 AR059775NIAMS NIH HHS R01 AR060574NIAMS NIH HHS R01 AR070854NIH HHS R01 AR059775NINDS NIH HHSOffice of Dietary Supplements
6 · The paper itself

Abstract

contextDeclining muscle strength and performance in older adults are associated with falls, fractures, and premature death.

objectiveThis work aimed to determine whether supplementation with vitamin D3 or omega-3 fatty acids vs placebo for 2 years improves physical performance measures.

methodsVITamin D and OmegA-3 TriaL (VITAL) was a double-blinded, placebo-controlled randomized trial of supplemental vitamin D3 and/or omega-3 fatty acids vs placebo in the prevention of cancer and cardiovascular disease in 25 871 US adults. This ancillary study was completed in a New England subcohort that had in-person evaluations at baseline and 2-year follow-up. This study was conducted with 1054 participants (age: men ≥50 and women ≥55 years) at the Center for Clinical Investigations in Boston. Interventions included a 2 × 2 factorial design of supplemental vitamin D3 (cholecalciferol, 2000 IU/day) and/or marine omega-3 fatty acids (1 g/day). Main outcome measures included 2-year changes in physical performance measures of grip strength, walking speed, standing balance, repeated chair stands, and Timed-up and Go (TUG).

resultsAt 2 years, all randomized groups showed worsening walking speeds and TUG. There were no differences in changes in grip strength, walking speeds, Short Physical Performance Battery (composite of walking speed, balance, and chair stands), and TUG between the vitamin D3-treated and the placebo-treated groups and between the omega-3-treated and the placebo-treated groups. Effects overall did not vary by sex, age, body mass index, or baseline measures of total or free 25-hydroxyvitamin D (25[OH]D) or plasma omega-3 index; TUG slightly worsened with vitamin D supplementation, compared to placebo, in participants with baseline total 25(OH)D levels above the median (P = .01; P for interaction = .04).

conclusionNeither supplemental vitamin D3 nor marine omega-3 fatty acids for 2 years improved physical performance in this generally healthy adult population.

Indexed as

CholecalciferolDietary SupplementsFatty Acids, Omega-3Physical Functional PerformanceAgedDouble-Blind MethodFemaleFollow-Up StudiesHand StrengthHumansMaleMiddle AgedMuscle StrengthVitamin DCholecalciferolFatty Acids, Omega-3Vitamin Domega-3 fatty acidsphysical performancevitamin D

Identifiers

PMID38488491
PMCPMC11651677
OpenAlexW4392886269

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.